|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar
|
|
2
|
Green VL: Breast cancer risk assessment,
prevention and the future. Obstet Gynecol Clin North Am.
40:525–549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allen-Petersen BL, Carter CJ, Ohm AM and
Reyland ME: Protein kinase Cdelta is required for ErbB2-driven
mammary gland tumorigenesis and negatively correlates with
prognosis in human breast cancer. Oncogene. 33:1306–1315. 2014.
View Article : Google Scholar
|
|
4
|
Chlebowski RT, Col N, Winer EP, Collyar
DE, Cummings SR, Vogel VG III, Burstein HJ, Eisen A, Lipkus I and
Pfister DG: American Society of clinical oncology technology
assessment of pharmacologic interventions for breast cancer risk
reduction including tamoxifen, raloxifene and aromatase inhibition.
J Clin Oncol. 20:3328–3343. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Visvanathan K, Hurley P and Bantug E: Use
of pharmacologic interventions for breast cancer risk reduction:
american society of clinical oncology clinical practice guideline.
J Clin Oncol. 31:2942–2962. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jordan VC: Tamoxifen as the first targeted
long-term adjuvant therapy for breast cancer. Endocr Relat Cancer.
21:R235–R246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sukawa Y, Yamamoto H, Nosho K, et al: HER2
expression and PI3K-Akt pathway alterations in gastric cancer.
Digestion. 89:12–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chiang CT, Way TD, Tsai SJ and Lin JK:
Diosgenin, a naturally occurring steroid, suppresses fatty acid
synthase expression in HER2-overexpressing breast cancer cells
through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett.
581:5735–5742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang MH, Man HT, Zhao XD, Dong N and Ma
SL: Estrogen receptor-positive breast cancer molecular signatures
and therapeutic potentials (Review). Biomed Rep. 2:41–52.
2014.PubMed/NCBI
|
|
10
|
Daniel KG, Gupta P, Harbach RH, Guida WC
and Dou QP: Organic copper complexes as a new class of proteasome
inhibitors and apoptosis inducers in human cancer cells. Biochem
Pharmacol. 67:1139–1151. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cen D, Brayton D, Shahandeh B, Meyskens FL
Jr and Farmer PJ: Disulfiram facilitates intracellular Cu uptake
and induces apoptosis in human melanoma cells. J Med Chem.
47:6914–6920. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rizk SL and Sky-Peck HH: Comparison
between concentrations of trace elements in normal and neoplastic
human breast tissue. Cancer Res. 44:5390–5394. 1984.PubMed/NCBI
|
|
13
|
Daniel KG, Harbach RH, Guida WC and Dou
QP: Copper storage diseases: Menkes, Wilsons and cancer. Front
Biosci. 9:2652–2662. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang YL, Sheu JY and Lin TH: Association
between oxidative stress and changes of trace elements in patients
with breast cancer. Clin Biochem. 32:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang H, Chen D, Ringler J, Chen W, Cui
QC, Ethier SP, Dou QP and Wu G: Disulfiram treatment facilitates
phosphoinositide 3-kinase inhibition in human breast cancer cells
in vitro and in vivo. Cancer Res. 70:3996–4004. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jørgensen CH, Pedersen B and Tønnesen H:
The efficacy of disulfiram for the treatment of alcohol use
disorder. Alcohol Clin Exp Res. 35:1749–1758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, McLeod HL and Cassidy J:
Disulfiram-mediated inhibition of NF-kappaB activity enhances
cytotoxicity of 5-fluorouracil in human colorectal cancer cell
lines. Int J Cancer. 104:504–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen D, Cui QC, Yang H and Dou QP:
Disulfiram, a clinically used anti-alcoholism drug and
copper-binding agent, induces apoptotic cell death in breast cancer
cultures and xenografts via inhibition of the proteasome activity.
Cancer Res. 66:10425–10433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Doyon G, Zerbato J, Mellors JW and
Sluis-Cremer N: Disulfiram reactivates latent HIV-1 expression
through depletion of the phosphatase and tensin homolog. AIDS.
27:F7–F11. 2013. View Article : Google Scholar
|
|
20
|
Conticello C, Martinetti D, Adamo L, et
al: Disulfiram, an old drug with new potential therapeutic uses for
human hematological malignancies. Int J Cancer. 131:2197–2203.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ursini-Siegel J, Schade B, Cardiff RD and
Muller WJ: Insights from transgenic mouse models of ERBB2-induced
breast cancer. Nat Rev Cancer. 7:389–397. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu
X, Hilsenbeck SG, Bissonnette RP, Lamph WW and Brown PH: The
Rexinoid LG100268 prevents the development of preinvasive and
invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin
Cancer Res. 13:6224–6231. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee HJ, So JY, DeCastro A, Smolarek A,
Paul S, Maehr H, Uskokovic M and Suh N: Gemini vitamin D analog
suppresses ErbB2-positive mammary tumor growth via inhibition of
ErbB2/AKT/ERK signaling. J Steroid Biochem Mol Biol. 121:408–412.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang GP, Han D, Liu G, Gao SG, Cai XQ,
Duan RH and Feng XS: Effects of soy isoflavone and endogenous
oestrogen on breast cancer in MMTV-erbB2 transgenic mice. J Int Med
Res. 40:2073–2082. 2012. View Article : Google Scholar
|
|
25
|
Wattenberg LW: Chemoprevention of cancer.
Cancer Res. 45:1–8. 1985.PubMed/NCBI
|
|
26
|
Bertram JS, Kolonel LN and Meyskens FL Jr:
Rationale and strategies for chemoprevention of cancer in humans.
Cancer Res. 47:3012–3031. 1987.PubMed/NCBI
|
|
27
|
Santner SJ, Dawson PJ, Tait L, Soule HD,
Eliason J, Mohamed AN, Wolman SR, Heppner GH and Miller FR:
Malignant MCF10CA1 cell lines derived from premalignant human
breast epithelial MCF10AT cells. Breast Cancer Res Treat.
65:101–110. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu J, Xiong G, Trinkle C and Xu R:
Integrated extracellular matrix signaling in mammary gland
development and breast cancer progression. Histol Histopathol.
2014.
|
|
29
|
Lövborg H, Oberg F, Rickardson L, Gullbo
J, Nygren P and Larsson R: Inhibition of proteasome activity,
nuclear factor-KappaB translocation and cell survival by the
antialcoholism drug disulfiram. Int J Cancer. 118:1577–1580. 2006.
View Article : Google Scholar
|
|
30
|
Li L, Yang H, Chen D, Cui C and Dou QP:
Disulfiram promotes the conversion of carcinogenic cadmium to a
proteasome inhibitor with pro-apoptotic activity in human cancer
cells. Toxicol Appl Pharmacol. 229:206–214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brar SS, Grigg C and Wilson KS: Disulfiram
inhibits activating transcription factor/cyclic AMP-responsive
element binding protein and human melanoma growth in a
metal-dependent manner in vitro, in mice and in a patient with
metastatic disease. Mol Cancer Ther. 3:1049–1060. 2004.PubMed/NCBI
|
|
32
|
den Hollander P, Savage MI and Brown PH:
Targeted therapy for breast cancer prevention. Front Oncol.
3:2502013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brown P: Prevention: targeted
therapy-anastrozole prevents breast cancer. Nat Rev Clin Oncol.
11:127–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
